TY - JOUR

T1 - Pharmacogenetics of antiemetics for chemotherapy-induced nausea and vomiting

T2 - A systematic review and meta-analysis

AU - Eliasen, Astrid

AU - Dalhoff, Kim

AU - Mathiasen, René

AU - Schmiegelow, Kjeld

AU - Rechnitzer, Catherine

AU - Schelde, Astrid Blicher

AU - Perwitasari, Dyah Aryani

AU - Tsuji, Daiki

AU - Brok, Jesper

PY - 2020/5

Y1 - 2020/5

N2 - A substantial proportion of cancer patients experience chemotherapy-induced nausea and vomiting (CINV) despite the use of antiemetic drugs. Prevalent genetic polymorphisms involved in antiemetic drug metabolism, drug transport and receptor pathways likely affect the effectiveness of antiemetics. Knowledge on which polymorphisms to integrate into individualised clinical care is needed. We did a systematic review evaluating the association between polymorphisms and effectiveness of antiemetics in cancer patients receiving moderately to highly emetogenic chemotherapy. Twenty studies n = 2331 evaluated eight polymorphisms in five candidate genes involved in 5-HT3 antagonist pathways. HTR3C C1214G increased the risk of acute chemotherapy-induced vomiting in the dominant model (odds ratio (OR) = 2.67, 95 % confidence interval (CI): 1.08–6.63). ABCB1 C3435T reduced the risk of acute CINV in the recessive model (OR = 0.60, 95 % CI: 0.44-0.81). Future studies should evaluate candidate genes that affect pharmacogenetics of other antiemetics beside 5-HT3 antagonists.

AB - A substantial proportion of cancer patients experience chemotherapy-induced nausea and vomiting (CINV) despite the use of antiemetic drugs. Prevalent genetic polymorphisms involved in antiemetic drug metabolism, drug transport and receptor pathways likely affect the effectiveness of antiemetics. Knowledge on which polymorphisms to integrate into individualised clinical care is needed. We did a systematic review evaluating the association between polymorphisms and effectiveness of antiemetics in cancer patients receiving moderately to highly emetogenic chemotherapy. Twenty studies n = 2331 evaluated eight polymorphisms in five candidate genes involved in 5-HT3 antagonist pathways. HTR3C C1214G increased the risk of acute chemotherapy-induced vomiting in the dominant model (odds ratio (OR) = 2.67, 95 % confidence interval (CI): 1.08–6.63). ABCB1 C3435T reduced the risk of acute CINV in the recessive model (OR = 0.60, 95 % CI: 0.44-0.81). Future studies should evaluate candidate genes that affect pharmacogenetics of other antiemetics beside 5-HT3 antagonists.

KW - Antiemetics

KW - Antineoplastic agents

KW - Genetic polymorphism

KW - Meta-analysis

KW - Nausea

KW - Neoplasms

KW - Vomiting

U2 - 10.1016/j.critrevonc.2020.102939

DO - 10.1016/j.critrevonc.2020.102939

M3 - Review

C2 - 32259776

AN - SCOPUS:85082764518

VL - 149

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

M1 - 102939

ER -